Disclosures for "Expanded Clinical Phenotype and Untargeted Metabolomics Analysis in RARS2-related Mitochondrial Disorder"
-
Dr. Walimbe has nothing to disclose.
-
Dr. Machol has nothing to disclose.
-
Dr. Kralik has nothing to disclose.
-
Ms. Mizerik has nothing to disclose.
-
Dr. Gofin has nothing to disclose.
-
Mir Reza Bekheirnia has nothing to disclose.
-
Dr. Gijavanekar has nothing to disclose.
-
Sarah Elsea has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dicerna. Sarah Elsea has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers. The institution of Sarah Elsea has received research support from NIH. The institution of Sarah Elsea has received research support from Speragen. The institution of Sarah Elsea has received research support from PTC Therapeutics. The institution of Sarah Elsea has received research support from PRISMS, Inc. The institution of Sarah Elsea has received research support from Smith-Magenis Syndrome Research Foundation. The institution of Sarah Elsea has received research support from Jerome Lejeune Foundation.
-
Dr. Emrick has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Arkema. The institution of Dr. Emrick has received research support from Lysogene. The institution of Dr. Emrick has received research support from PTC. The institution of Dr. Emrick has received research support from Roche. The institution of Dr. Emrick has received research support from NIH.
-
Prof. Scaglia has nothing to disclose.